Roivant Sciences Ltd.
ROIV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001635088
In the last 90 days, Roivant Sciences Ltd. insiders filed 0 open-market purchases and 11 sales; 503 institutions reported holding it in 13F filings for Q2 2026, worth $19.7B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 2, 2026 | May 29, 2025 | May 30, 2024 | Jun 28, 2023 | May 24, 2022 |
| Revenue | $8.26M | $29.1M | $124.8M | $61.3M | $55.3M |
| Operating expenses | $1.29B | $1.14B | $1.23B | $1.24B | $1.41B |
| Research and development | $681.8M | $550.4M | $501.7M | $525.2M | $483.0M |
| Selling, general and administrative | $610.5M | $591.4M | $687.4M | $600.5M | $775.0M |
| Operating income | -$515.1M | -$1.00B | $4.24B | -$1.18B | -$1.35B |
| Interest expense | – | – | $34.8M | $28.0M | $7.04M |
| Income tax | $133.3M | $48.2M | $22.2M | $5.19M | $369.0K |
| Net income | -$299.8M | -$172.0M | $4.35B | -$1.01B | -$845.3M |
| EPS, basic | $-0.43 | $-0.24 | $5.55 | $-1.42 | – |
| EPS, diluted | $-0.54 | $-0.24 | $5.23 | $-1.42 | – |
| Weighted shares, basic | 693.9M | 725.4M | 783.2M | 712.8M | – |
| Weighted shares, diluted | 693.9M | 725.4M | 831.0M | 712.8M | – |
| Margins and growth | |||||
| Operating margin | -6235.7% | -3453.3% | 3399.2% | -1917.9% | -2444.8% |
| Net margin | -3629.2% | -592.0% | 3484.9% | -1646.6% | -1528.9% |
| Revenue growth, year over year | −71.6% | −76.7% | +103.6% | +10.8% | – |
| Net income growth, year over year | – | −104.0% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 2, 2026 | May 29, 2025 | May 30, 2024 | Jun 28, 2023 | May 24, 2022 |
| Cash and equivalents | $1.42B | $2.72B | $6.54B | $1.68B | $2.06B |
| Short-term investments | $2.87B | $2.17B | – | – | – |
| Accounts receivable | – | – | $53.5M | $30.4M | – |
| Inventory | – | – | $35.3M | $2.76M | – |
| Total current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B |
| Property, plant and equipment | $12.0M | $12.1M | $19.1M | $39.1M | $25.9M |
| Intangible assets | – | – | $137.8M | $144.9M | – |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Accounts payable | $18.0M | $23.7M | $53.2M | $37.8M | $34.6M |
| Short-term debt | – | – | $12.0M | $40.7M | $0 |
| Total current liabilities | $281.2M | $149.4M | $266.8M | $272.4M | $184.4M |
| Long-term debt | – | – | $430.6M | $375.5M | $210.0M |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Shareholders' equity | $5.29B | $5.19B | $6.45B | $1.61B | $2.04B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Apr 2, 2026 | May 29, 2025 | May 30, 2024 | Jun 28, 2023 | May 24, 2022 |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Capital expenditures | $8.21M | $4.60M | $1.38M | $12.7M | $17.4M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Depreciation and amortization | $3.35M | $14.1M | $22.0M | $18.9M | – |
| Stock-based compensation | $346.2M | $289.0M | $199.6M | $217.8M | $565.0M |
| Share buybacks | – | $1.29B | – | – | – |
| Investing cash flow | -$682.3M | -$1.77B | $5.20B | -$44.3M | $303.3M |
| Financing cash flow | $134.2M | -$1.22B | $419.4M | $499.5M | $306.8M |
| Net change in cash | -$1.29B | -$3.82B | $4.86B | -$381.9M | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4190.9% | 994.8% | 160.0% | 355.4% | 1021.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 724.6M | +4.2% | SEC |
| Jul 31, 2026 | 722.3M | +5.8% | SEC |
| May 12, 2026 | 719.3M | +5.8% | SEC |
| Feb 2, 2026 | 715.7M | +0.3% | SEC |
| Nov 3, 2025 | 695.5M | −4.5% | SEC |
| Aug 6, 2025 | 682.9M | −7.7% | SEC |
| May 21, 2025 | 679.8M | −8.0% | SEC |
| Feb 6, 2025 | 713.5M | −11.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.